Dr. Warner W. Carr, MD
Allergy & Immunology (Allergy Physician)
- Medicare participating
At a glance
- Medical school
- University of Washington School of Medicine (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 191
Licensed in California since 2007, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: University of Washington School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy Physician primary
CA license A-98901 (first issued 2007; current) · MD license D0062093 -
Internal Medicine Physician
MD license D0062093
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Providence Mission Hospital Mission Viejo, CA
Medical groups
- Allergy and Asthma Associates of Southern Calif Inc (6 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 191
- Services billed
- 5,955
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Test for allergy using allergenic extract | 2,395 | 52 |
| Professional service for preparation and provision of 1 or more antigens | 536 | 30 |
| Professional service for multiple injections of allergen | 422 | 36 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 348 | 26 |
| Established patient office or other outpatient visit, 30-39 minutes | 222 | 137 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 193 | 28 |
| Test for allergy using allergenic extract injected into skin | 102 | 11 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 96 | 15 |
| Test to measure expiratory airflow and volume | 95 | 66 |
| New patient office or other outpatient visit, 45-59 minutes | 67 | 67 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ipratropium Bromide Other prescribers in Laguna Niguel, CA | 172 |
| Azelastine Hcl Other prescribers in Laguna Niguel, CA | 166 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Laguna Niguel, CA | 125 |
| Fluticasone Propionate Other prescribers in Laguna Niguel, CA | 114 |
| Montelukast Sodium Other prescribers in Laguna Niguel, CA | 109 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Laguna Niguel, CA | 75 |
| Tezspire (tezepelumab-ekko) | 73 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in Laguna Niguel, CA | 68 |
| Hydroxyzine Hcl Other prescribers in Laguna Niguel, CA | 49 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in Laguna Niguel, CA | 47 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 34 companies reported 288 payments worth $130,920 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $28,580 |
|---|---|
| Ars Pharmaceuticals Operations, Inc. | $27,036 |
| Genzyme Corporation | $23,862 |
| Merz North America, Inc. | $13,967 |
| Lilly USA, LLC | $9,609 |
| Regeneron Healthcare Solutions, Inc. | $8,671 |
| Novartis Pharmaceuticals Corporation | $5,639 |
| Aquestive Therapeutics, Inc. | $4,207 |
| Compensation for services other than consulting (speaking, faculty) | $55,296 |
|---|---|
| Consulting Fee | $53,750 |
| Travel and Lodging | $11,838 |
| Food and Beverage | $7,377 |
| Honoraria | $2,660 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Apr 9, 2025 | Consulting Fee | $8,944 |
| Ars Pharmaceuticals Operations, Inc. Mar 5, 2025 | Compensation for services other than consulting (speaking, faculty) NEFFY · ALLERGY | $8,625 |
| Ars Pharmaceuticals Operations, Inc. Mar 12, 2025 | Compensation for services other than consulting (speaking, faculty) NEFFY · ALLERGY | $8,625 |
| Lilly USA, LLC Nov 24, 2025 | Consulting Fee EBGLYSS · Immunology Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $6,000 |
| Merz North America, Inc. Jul 1, 2025 | Consulting Fee Xeomin · Dermatology | $4,893 |
| Merz North America, Inc. Dec 18, 2025 | Consulting Fee Xeomin · Dermatology | $4,500 |
| AstraZeneca Pharmaceuticals LP Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $4,300 |
| AstraZeneca Pharmaceuticals LP May 6, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $4,300 |
| Aquestive Therapeutics, Inc. Nov 18, 2025 | Consulting Fee LIBERVANT · Central Nervous System | $3,965 |
| Incyte Corporation Oct 14, 2025 | Consulting Fee OPZELURA · Dermatology | $3,748 |
All 67 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Merz North America, Inc. Dec 18, 2025 | Consulting Fee Xeomin · Dermatology | $4,500 |
| AstraZeneca Pharmaceuticals LP Dec 11, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $1,400 |
| Genzyme Corporation Dec 10, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $2,097 |
| Genzyme Corporation Dec 10, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $699 |
| Genzyme Corporation Dec 9, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $2,097 |
| Lilly USA, LLC Nov 24, 2025 | Consulting Fee EBGLYSS · Immunology Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $6,000 |
| Lilly USA, LLC Nov 24, 2025 | Consulting Fee EBGLYSS · Immunology | $2,800 |
| AstraZeneca Pharmaceuticals LP Nov 24, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $1,400 |
| AstraZeneca Pharmaceuticals LP Nov 24, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $450 |
| Aquestive Therapeutics, Inc. Nov 18, 2025 | Consulting Fee LIBERVANT · Central Nervous System | $3,965 |
| Lilly USA, LLC Nov 14, 2025 | Travel and Lodging travel to INDIANAPOLIS, IL · in-kind | $715 |
| AstraZeneca Pharmaceuticals LP Nov 4, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $125 |
| Adma Biomanufacturing LLC Nov 4, 2025 | Consulting Fee | $19.37 |
| AstraZeneca Pharmaceuticals LP Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $250 |
| AstraZeneca Pharmaceuticals LP Oct 27, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $250 |
| Incyte Corporation Oct 14, 2025 | Consulting Fee OPZELURA · Dermatology | $3,748 |
| Novartis Pharmaceuticals Corporation Oct 2, 2025 | Consulting Fee | $1,856 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Consulting Fee | $3,375 |
| AstraZeneca Pharmaceuticals LP Jul 10, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $2,150 |
| Merz North America, Inc. Jul 1, 2025 | Consulting Fee Xeomin · Dermatology | $4,893 |
| AstraZeneca Pharmaceuticals LP Jun 2, 2025 | Consulting Fee AIRSUPRA · Respiratory | $537 |
| AstraZeneca Pharmaceuticals LP May 29, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $2,150 |
| AstraZeneca Pharmaceuticals LP May 15, 2025 | Travel and Lodging TEZSPIRE · Respiratory · travel to Irvine, CA · in-kind Company’s descriptionSpeaker Expenses | $19.88 |
| AstraZeneca Pharmaceuticals LP May 8, 2025 | Travel and Lodging AIRSUPRA · Respiratory · travel to Anaheim, CA · in-kind Company’s descriptionSpeaker Expenses | $34.02 |
| AstraZeneca Pharmaceuticals LP May 6, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $4,300 |
| Merz North America, Inc. May 2, 2025 | Travel and Lodging Xeomin · travel to Austin, TX · in-kind | $383 |
| AstraZeneca Pharmaceuticals LP Apr 25, 2025 | Travel and Lodging TEZSPIRE · Respiratory · travel to Lost Pines, TX · in-kind Company’s descriptionSpeaker Expenses | $867 |
| AstraZeneca Pharmaceuticals LP Apr 25, 2025 | Travel and Lodging TEZSPIRE · Respiratory · travel to Lost Pines, TX · in-kind Company’s descriptionSpeaker Expenses | $599 |
| AstraZeneca Pharmaceuticals LP Apr 25, 2025 | Travel and Lodging TEZSPIRE · Respiratory · travel to Lost Pines, TX · in-kind Company’s descriptionSpeaker Expenses | $338 |
| Regeneron Healthcare Solutions, Inc. Apr 18, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $2,097 |
| Regeneron Healthcare Solutions, Inc. Apr 18, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $699 |
| AstraZeneca Pharmaceuticals LP Apr 16, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $537 |
| Regeneron Healthcare Solutions, Inc. Apr 15, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $2,738 |
| Regeneron Healthcare Solutions, Inc. Apr 15, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,621 |
| AstraZeneca Pharmaceuticals LP Apr 14, 2025 | Consulting Fee FASENRA · Respiratory | $537 |
| Genzyme Corporation Apr 9, 2025 | Consulting Fee | $8,944 |
| Ars Pharmaceuticals Operations, Inc. Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) NEFFY · ALLERGY | $1,150 |
| Genzyme Corporation Apr 9, 2025 | Travel and Lodging travel to Houston, TX · in-kind | $712 |
| Genzyme Corporation Apr 9, 2025 | Travel and Lodging travel to Houston, TX | $650 |
| Genzyme Corporation Apr 9, 2025 | Travel and Lodging travel to Houston, TX · in-kind | $386 |
| Genzyme Corporation Apr 9, 2025 | Travel and Lodging travel to Houston, TX | $358 |
| Ars Pharmaceuticals Operations, Inc. Apr 9, 2025 | Travel and Lodging NEFFY · ALLERGY · travel to SOUTHLAKE, TX | $311 |
| Genzyme Corporation Apr 9, 2025 | Travel and Lodging travel to Houston, TX · in-kind | $293 |
| Ars Pharmaceuticals Operations, Inc. Apr 9, 2025 | Travel and Lodging NEFFY · ALLERGY · travel to SOUTHLAKE, TX | $218 |
| Genzyme Corporation Apr 8, 2025 | Consulting Fee | $2,064 |
| Genzyme Corporation Apr 8, 2025 | Travel and Lodging travel to San Antonio, TX · in-kind | $279 |
| Ars Pharmaceuticals Operations, Inc. Apr 2, 2025 | Travel and Lodging NEFFY · ALLERGY · travel to AUSTIN, TX | $196 |
| AstraZeneca Pharmaceuticals LP Apr 1, 2025 | Consulting Fee AIRSUPRA · Respiratory | $1,074 |
| Genzyme Corporation Mar 27, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $2,447 |
| Genzyme Corporation Mar 26, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $2,447 |
| Blueprint Medicines Corporation Mar 14, 2025 | Honoraria AYVAKIT · Oncology / Rare Diseases | $2,660 |
| Merz North America, Inc. Mar 13, 2025 | Consulting Fee Xeomin · Dermatology | $3,000 |
| Ars Pharmaceuticals Operations, Inc. Mar 12, 2025 | Compensation for services other than consulting (speaking, faculty) NEFFY · ALLERGY | $8,625 |
| Ars Pharmaceuticals Operations, Inc. Mar 12, 2025 | Compensation for services other than consulting (speaking, faculty) NEFFY · ALLERGY | $1,150 |
| Ars Pharmaceuticals Operations, Inc. Mar 6, 2025 | Travel and Lodging NEFFY · ALLERGY · travel to SOUTHLAKE, TX · in-kind | $1,042 |
| Ars Pharmaceuticals Operations, Inc. Mar 6, 2025 | Travel and Lodging NEFFY · ALLERGY · travel to SOUTHLAKE, TX · in-kind | $767 |
| Ars Pharmaceuticals Operations, Inc. Mar 5, 2025 | Compensation for services other than consulting (speaking, faculty) NEFFY · ALLERGY | $8,625 |
| Adma Biomanufacturing LLC Mar 5, 2025 | Consulting Fee | $16.70 |
| AstraZeneca Pharmaceuticals LP Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $4,300 |
| Ars Pharmaceuticals Operations, Inc. Feb 25, 2025 | Travel and Lodging NEFFY · ALLERGY · travel to AUSTIN, TX · in-kind | $548 |
| Ars Pharmaceuticals Operations, Inc. Feb 25, 2025 | Travel and Lodging NEFFY · ALLERGY · travel to AUSTIN, TX · in-kind | $410 |
| AstraZeneca Pharmaceuticals LP Feb 18, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $375 |
| AstraZeneca Pharmaceuticals LP Feb 13, 2025 | Travel and Lodging AIRSUPRA · Respiratory · travel to Kohala Coast, HI · in-kind Company’s descriptionSpeaker Expenses | $1,533 |
| AstraZeneca Pharmaceuticals LP Feb 13, 2025 | Travel and Lodging AIRSUPRA · Respiratory · travel to Kohala Coast, HI · in-kind Company’s descriptionSpeaker Expenses | $1,177 |
| Ars Pharmaceuticals Operations, Inc. Jan 29, 2025 | Compensation for services other than consulting (speaking, faculty) NEFFY · ALLERGY | $3,450 |
| AstraZeneca Pharmaceuticals LP Jan 16, 2025 | Consulting Fee | $537 |
| AstraZeneca Pharmaceuticals LP Jan 3, 2025 | Consulting Fee | $2,551 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 17 industry-funded studies in 2025, from 10 companies. The companies reported $248,887 in research payments for these studies, mostly to the institutions running them.
- A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
Eli Lilly and Company · Active, not recruiting · NCT06339008 - Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630
AstraZeneca Pharmaceuticals LP - A phase 3, 52-week, randomized, double-blind, placebo-controlled, para
GlaxoSmithKline, LLC. - Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)
Regeneron Pharmaceuticals, Inc. · Completed · NCT02612454 - A randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with as…
AstraZeneca UK Limited - A randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with as…
AstraZeneca Pharmaceuticals LP - A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
Sanofi US Services Inc. · Completed · NCT06181435 - A phase 2 randomized doubleblind placebocontrolled parallelgroup doseranging study to investigate the efficacy and safety of PF07275315 in adult participants with inadequately controlled moderatetosevere asthma
Pfizer Inc. - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
AbbVie Inc. · Active, not recruiting · NCT06389136 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
AbbVie Inc. · Active, not recruiting · NCT03568318
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.